Longevity Drug Index / Rapamycin
Rapamycin
A transplant drug that is the most consistently life-extending compound ever tested in mice.
How it works
Rapamycin blocks mTORC1, a protein complex that senses nutrients, insulin and growth signals and tells cells to grow and divide. When mTORC1 is turned down, cells shift from growth to maintenance and step up autophagy, the process that breaks down and recycles damaged proteins and cell parts. At high, continuous doses it also blocks a second complex, mTORC2, which is linked to many of its metabolic side effects.
How it could help longevity
Lowering mTOR activity extends life in yeast, worms, flies and mice, and the same pathway is thought to explain part of the benefit of eating less. In older mice, short courses of rapamycin have improved heart function, immune responses and gum health. Researchers now favour low or weekly doses, which aim to block mTORC1 while sparing mTORC2.
Animal studies
- NIA Interventions Testing Program, 2009Rapamycin started at 20 months of age, roughly 60 in human years, extended lifespan in both male and female mice across three independent labs. It was the first drug shown to do this when started late in life.
- Higher doses, 2014Follow-up work found the effect grows with dose, with median lifespan gains of around 23% in males and 26% in females at the highest dose tested.
- Short courses, 2016A three-month course in middle-aged mice extended remaining life expectancy, suggesting continuous lifelong use may not be needed.
- Other speciesLifespan gains have also been seen in yeast, worms and flies. A trial in companion dogs (the Dog Aging Project) is under way.
Human studies
- Immune response in older adults, 2014Six weeks of a low dose of everolimus, a close relative of rapamycin, improved flu vaccine responses by about 20% in people over 65.
- Safety studies in healthy older adultsSmall trials of low daily or weekly doses for 8 weeks to a year found rapamycin was generally well tolerated, with mouth ulcers the most common complaint.
- PEARL trial, 2025A year-long placebo-controlled trial of weekly low-dose rapamycin in healthy adults aged 50 to 85 found it safe, with small signals of benefit in some secondary measures but no clear effect on its main outcome.
- VITAL-H trialA placebo-controlled trial funded by the US agency ARPA-H and led by UT Health San Antonio will test rapamycin, alongside semaglutide and dapagliflozin, in adults in their 60s.
Safety and side effects
At transplant doses rapamycin suppresses the immune system and can raise blood sugar and cholesterol, slow wound healing and cause mouth ulcers. It interacts with many drugs and with grapefruit. The low, intermittent doses used in aging research appear far better tolerated, but their long-term effects in healthy people are unknown.
Our view
The animal evidence is the strongest of any drug: replicated, in both sexes, and effective when started late. What is missing is a large, long human trial showing it slows aging or delays disease. Until then it remains a promising research drug, not a proven treatment.
Sources
- Harrison et al., Nature 2009: rapamycin fed late in life extends lifespan in mice
- Miller et al., Aging Cell 2014: rapamycin lifespan gains are dose and sex dependent
- Bitto et al., eLife 2016: transient rapamycin treatment in middle-aged mice
- Mannick et al., Sci Transl Med 2014: mTOR inhibition improves immune function in the elderly
- PEARL trial: low-dose rapamycin in healthy aging adults
- ClinicalTrials.gov: registered studies of Rapamycin
Links open PubMed or ClinicalTrials.gov searches for each study.
Last reviewed 11 November 2026. General information, not medical advice. None of these drugs is approved to slow aging.